Status: Not yet recruiting
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2).
Participants needed: 180
Trial details
Phase: Phase 3Age: 18-74Biological sex: AllType: InterventionalSponsor: AmgenUpdated: May 20, 2026
Eligibility criteria
Signed informed consent. [+8]
Diagnosis of definitive overlap autoimmune liver or rheumatologic syndrome with... [+74]